ATE294594T1 - Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung - Google Patents

Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung

Info

Publication number
ATE294594T1
ATE294594T1 AT99912502T AT99912502T ATE294594T1 AT E294594 T1 ATE294594 T1 AT E294594T1 AT 99912502 T AT99912502 T AT 99912502T AT 99912502 T AT99912502 T AT 99912502T AT E294594 T1 ATE294594 T1 AT E294594T1
Authority
AT
Austria
Prior art keywords
polynucleotide
composition
polynucleotide composition
lyophilized
cryoprotectant
Prior art date
Application number
AT99912502T
Other languages
English (en)
Inventor
Shankar Musunuri
Patrick P Deluca
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE294594T1 publication Critical patent/ATE294594T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99912502T 1998-03-13 1999-03-12 Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung ATE294594T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7808098P 1998-03-13 1998-03-13
PCT/US1999/005547 WO1999045966A1 (en) 1998-03-13 1999-03-12 Polynucleotide composition, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
ATE294594T1 true ATE294594T1 (de) 2005-05-15

Family

ID=22141799

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912502T ATE294594T1 (de) 1998-03-13 1999-03-12 Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung

Country Status (14)

Country Link
US (1) US20080081366A1 (de)
EP (1) EP1061955B1 (de)
JP (1) JP2002506048A (de)
KR (1) KR100625385B1 (de)
CN (1) CN100471522C (de)
AT (1) ATE294594T1 (de)
AU (1) AU765177B2 (de)
BR (1) BR9908754A (de)
CA (1) CA2322232A1 (de)
DE (1) DE69925113T2 (de)
ES (1) ES2239440T3 (de)
IL (1) IL138306A0 (de)
PT (1) PT1061955E (de)
WO (1) WO1999045966A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329129C (en) * 1998-05-22 2009-02-24 Sumitomo Pharmaceuticals Company, Limited Stable gene formulations comprising saccharides
AU5345999A (en) * 1998-08-14 2000-03-06 Valentis, Inc. Protected one-vial formulation for nucleic acid molecules, methods of making thesame by in-line mixing, and related products and methods
EP1230338B1 (de) * 1999-11-19 2006-03-08 Zycos Inc. Durchflussverfahren zur herstellung von mikropartikeln
JP2001316297A (ja) * 2000-02-23 2001-11-13 Kaken Pharmaceut Co Ltd 遺伝子包埋リポソーム製剤及びその製法
EP1456377B1 (de) * 2001-12-20 2019-06-12 Merck Sharp & Dohme Corp. Syn3-zusammensetzungen und verfahren
AU2003218168A1 (en) * 2002-03-15 2003-09-29 University Of Southern California Ophthalmic solutions for delivery of expression vectors
US7615229B2 (en) 2002-03-15 2009-11-10 Wyeth Holdings Corporation Mutants of the P4 protein of nontypable Haemophilus influenzae with reduced enzymatic activity
WO2004060363A1 (en) 2002-12-23 2004-07-22 Vical Incorporated Method for producing sterile polynucleotide based medicaments
EP1578193A4 (de) * 2002-12-23 2011-06-15 Vical Inc Gefriertrocknungsverfahren für nukleinsäure-/blockcopolymer-/kationtensid-komplexe
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
ES2564241T3 (es) * 2005-12-02 2016-03-21 Glaxosmithkline Biologicals Sa Nanopartículas para su uso en composiciones inmunogénicas
KR100777249B1 (ko) 2006-02-14 2007-11-28 (주)바이오니아 건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
DE102006038240A1 (de) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Verfahren zur Herstellung eines Komposits aus Oligo- oder Polynucleotiden und hydrophoben biodegradierbaren Polymeren sowie nach dem Verfahren erhaltenes Komposit
GB0701253D0 (en) * 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
EP1970441A1 (de) * 2007-03-06 2008-09-17 BioAlliance Pharma Plasmid mit einer Sequenz, die eine Disintegrin-Domäne von Metargidin (RDD) kodiert
US20090258932A1 (en) * 2008-04-09 2009-10-15 Viromed Co., Ltd. Lyophilized DNA Formulations for Enhanced Expression of Plasmid DNA
EP3998064A1 (de) 2011-06-08 2022-05-18 Translate Bio, Inc. Spaltbare lipide
WO2014015091A2 (en) 2012-07-19 2014-01-23 Zoetis Llc Bovine influenza virus compositions
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
KR101779775B1 (ko) 2013-10-22 2017-09-21 주식회사 바이로메드 간세포 성장인자의 둘 이상의 이형체를 이용한 근위축성 측삭 경화증 예방 또는 치료용 조성물
EP3241903A4 (de) * 2014-12-29 2018-07-04 Bonac Corporation Zusammensetzung mit stabilem nukleinsäuremolekül
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
AU2016307935B2 (en) 2015-08-14 2022-08-18 The University Of Melbourne Mycoplasma bovis compositions
IL266264B2 (en) * 2016-11-04 2023-11-01 Baxalta Inc Adeno-associated virus formulations
WO2020014479A1 (en) 2018-07-11 2020-01-16 Baxalta Incorporated Aav compositions
EP3823677A4 (de) * 2018-07-19 2022-06-01 Helixmith Co., Ltd. Lyophilisierte pharmazeutische zusammensetzungen für nackte dna-gentherapie
CN110596227B (zh) * 2019-08-08 2021-11-23 河北省食品检验研究院（国家果类及农副加工产品质量监督检验中心、河北省食品安全实验室） 飞行时间质谱即用型斯坦利沙门氏菌定性标准样品的制备方法
US12426594B2 (en) 2020-09-24 2025-09-30 Everest Medical Innovation GmbH Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
US12453805B2 (en) 2020-09-24 2025-10-28 Everest Medical Innovation GmbH Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
KR102460006B1 (ko) * 2021-11-22 2022-10-27 주식회사 리엔젠 폴리뉴클레오타이드 및 히알루론산 포함하는 피부 필러 조성물의 동결건조 제조방법 및 이에 따라 제조된 폴리뉴클레오타이드 및 히알루론산 포함하는 피부 필러 조성물
CN119372199A (zh) * 2024-11-19 2025-01-28 郑州安图生物工程股份有限公司 干燥保护剂、干燥方法及核酸质控品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (en) * 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
US5709076A (en) * 1992-09-14 1998-01-20 Lawlor; Shawn P. Method and apparatus for power generation using rotating ramjet which compresses inlet air and expands exhaust gas against stationary peripheral wall
AU2215995A (en) * 1994-04-07 1995-10-30 Akzo Nobel N.V. Freeze-dried compositions comprising rna
WO1996027393A1 (en) * 1995-03-07 1996-09-12 University Of Pittsburgh A dry powder formulation for gene therapy
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
DE69732029T2 (de) * 1996-04-26 2006-02-23 Merck & Co., Inc. Dna enthaltende impfstoffen
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren

Also Published As

Publication number Publication date
ES2239440T3 (es) 2005-09-16
CN100471522C (zh) 2009-03-25
JP2002506048A (ja) 2002-02-26
EP1061955A1 (de) 2000-12-27
DE69925113D1 (de) 2005-06-09
KR100625385B1 (ko) 2006-09-18
US20080081366A1 (en) 2008-04-03
AU3086899A (en) 1999-09-27
BR9908754A (pt) 2000-11-28
KR20010074441A (ko) 2001-08-04
IL138306A0 (en) 2001-10-31
WO1999045966A1 (en) 1999-09-16
PT1061955E (pt) 2005-08-31
EP1061955B1 (de) 2005-05-04
CA2322232A1 (en) 1999-09-16
DE69925113T2 (de) 2006-01-19
AU765177B2 (en) 2003-09-11
CN1294520A (zh) 2001-05-09

Similar Documents

Publication Publication Date Title
ATE294594T1 (de) Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung
DE69932645D1 (de) Neue Fettsäureanaloge zur Behandlung der Fettleber
ATE264410T1 (de) Verfahren zur verbesserung der ductilität von nitinol
DE59100581D1 (de) Verfahren zur herstellung von torfersatz, anlage zur durchführung dieses verfahrens, anwendung des verfahrens und nach diesem verfahren hergestellter torfersatz.
DK0695408T3 (da) Fremgangsmåde til forbedring af celluloseholdige produkters modstandsevne over for skimmel og råd
DE60003912D1 (de) Verfahren zur herstellung von konditionierungstüchern
ATE321017T1 (de) Verfahren zur herstellung von 3,3-dimethylbutanal
ATE294152T1 (de) Substituierte tetrahydro-naphtaline und analoge verbindungen
ATE375090T1 (de) Bioaktive peptide, ihre verwendung und verfahren zu ihre herstellung
DE69911656D1 (de) Verfahren zur herstellung eines hydraulischen bindemittels auf der basis von anhydrite iii oder alpha und damit hergestelltes bindemittel
DE60119711D1 (de) Verfahren zur herstellung von funktionalierten polyalkyleniminen, diese enthaltende zusammenstellungen und ihre verwendungen
ATE238814T1 (de) Dendrimere fullerenderivate, verfahren zur herstellung und verwendung als neuroprotektiva
DE59107488D1 (de) Verfahren zur herstellung wasch- und reinigungsaktiver tensidgranulate
DE69221745D1 (de) Verfahren zur kombinierten Herstellung von organischen Zusammenstellungen und Energie
DE59106640D1 (de) Verfahren zur Herstellung von 1,3-Diketonen.
EP1555033A3 (de) Polynukleotidzusammensetzung, Verfahren zu deren Herstellung und Verwendung
MD940401A (ro) Compoziţie pentru decelerarea inflamării şi procedeu de decelerare a inflamării
DE69917669D1 (de) Glutaminsäure und glykolsäure verwendendes verfahren zur erhöhung der pflanzenproduktivität
ATE188201T1 (de) Verfahren zur herstellung von oligomethylenharnstoff
DE69103042D1 (de) Angiotensin-konvertierender Enzym-Inhibitor, Verfahren zu seiner Herstellung, diesen enthaltende Zusammensetzung und deren Verwendung.
ATE195547T1 (de) Antioxidantzusammensetzung und verfahren zu dessen herstellung
ATE286013T1 (de) Verfahren zur herstellung von polyhalogenierten para-trifluoroanilinen
ES2155911T3 (es) Derivados de alcanfor como nuevos odorantes.
ATE213734T1 (de) Verfahren zur herstellung von 1,3- disubstituierten 2-nitroguanidinen
DK1214315T5 (da) 1,4-Dihydropyridin-5-carboxylsyreesterderivater og fremgangsmåde til fremstilling af samme

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1061955

Country of ref document: EP

REN Ceased due to non-payment of the annual fee